首页> 外文期刊>Journal of Translational Medicine >Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model
【24h】

Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model

机译:在刘易斯肺癌异种移植小鼠模型中,通过环氧合酶-2介导的肺转移性炎症微环境,来氟平软膏联合塞来昔布抗肿瘤增强作用

获取原文
           

摘要

Fei-Liu-Ping (FLP) ointment is an oral prescription medication that has been widely applied to treat lung cancer patients in China. Regulation of the metastatic microenvironment is an important therapeutic approach for prevention and treatment of tumor recurrence and metastasis. The advantage of Traditional Chinese Medicine management of lung cancer lies in the prevention of recurrence and metastasis. Our previous study has demonstrated that FLP ointment could regulate lung inflammatory microenvironment in vitro. However, the effects of FLP on the tumor microenvironment in vivo are still poorly understood. The objective of this study is to investigate the effect of FLP alone or in combination with celecoxib in the prevention of lung cancer progression by Cyclooxygenase (Cox)-2 mediated tumor inflammatory microenvironment in vivo. 120 Lewis lung carcinoma xenograft mice were divided equally into four groups: vehicle, FLP, celecoxib, and FLP plus celecoxib. The dynamic growth of the xenografted tumors was observed using an in vivo fluorescence imaging system. Mice were sacrificed on day 14, day 21, and day 28, and tumor specimens and lung tissues were harvested to detect the metastasis-associated protein expression. Tumor inhibition rate was 15.4, 44.2, 47.4?% at day 14, 37.3, 34.7, 61.5?% at day 21, and 15.5, 10.3, 32.5?% at day 28 after treatment of FLP, celecoxib, and FLP plus celecoxib, respectively. Upon treatment of FLP and celecoxib together, lung metastasis rate was 30?% (8 metastatic nodules) lower than other groups. FLP inhibited Cox-2 expression in a time-dependent manner. Moreover, FLP inhibited N-cadherin, matrix metalloproteinases (MMP)-9, and Vimentin expression. Treatment of FLP in combination with celecoxib was more effective than FLP or celecoxib alone in inhibiting vascular endothelial growth factor, platelet-derived growth factor receptors β, microsomal Prostaglandin E synthase-1, MMP-2, MMP-9, N-cadherin, and Vimentin expression, but increased E-cadherin expression. FLP inhibited tumor growth and metastasis in a Lewis lung xenograft mice model through the Cox-2 pathway. FLP in combination with celecoxib enhanced the antitumor growth and anti-metastasis effects. Traditional Chinese herbs combined with anti-inflammatory drugs might offer a promising strategy to prevent tumor metastasis.
机译:非流平(FLP)软膏是一种口服处方药,在中国已广泛应用于治疗肺癌患者。转移微环境的调节是预防和治疗肿瘤复发和转移的重要治疗方法。中药治疗肺癌的优势在于可以预防复发和转移。我们以前的研究表明,FLP软膏可以在体外调节肺部炎症微环境。但是,FLP对体内肿瘤微环境的影响仍知之甚少。这项研究的目的是研究FLP单独或与塞来昔布联用在体内通过环氧合酶(Cox)-2介导的肿瘤炎症微环境预防肺癌进展的作用。将120只Lewis肺癌异种移植小鼠平均分为四组:媒介物,FLP,塞来昔布和FLP加塞来昔布。使用体内荧光成像系统观察异种移植肿瘤的动态生长。在第14天,第21天和第28天处死小鼠,并收集肿瘤标本和肺组织以检测与转移相关的蛋白质表达。 FLP,塞来昔布和FLP加塞来昔布治疗后第14天的肿瘤抑制率分别为15.4、44.2、47.4%,第21天的37.3、34.7、61.5%,以及第28天的15.5、10.3、32.5%。 。联合使用FLP和塞来昔布后,肺转移率比其他组低30%(8个转移性结节)。 FLP以时间依赖性方式抑制Cox-2表达。此外,FLP抑制N-钙黏着蛋白,基质金属蛋白酶(MMP)-9和波形蛋白的表达。 FLP与塞来昔布联合治疗比FLP或塞来昔布单独治疗在抑制血管内皮生长因子,血小板源性生长因子受体β,微粒体前列腺素E合酶-1,MMP-2,MMP-9,N-钙黏着蛋白和波形蛋白表达,但增加了E-钙粘蛋白表达。 FLP通过Cox-2途径抑制Lewis异种移植小鼠模型中的肿瘤生长和转移。 FLP与塞来昔布联合使用可增强抗肿瘤生长和抗转移作用。中草药与抗炎药的结合可能为预防肿瘤转移提供了一种有希望的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号